Understanding the binding capacity of FcRn is essential for the development of therapeutic antibodies as well as the study of drug pharmacokinetics and disease mechanisms. Creative Proteomics offers FcγRs affinity assay service that include a range of analytical techniques and expertise that can help clients to rapidly achieve accurate detection of intermolecular affinity.
Introduce of FcRn
FcRn (neonatal Fc receptor) is a protein that plays a crucial role in the transport and recycling of antibodies within the body. It is responsible for the protection and prolongation of the half-life of antibodies, thereby enhancing their therapeutic efficacy. The affinity of FcRn for antibodies is a critical factor in this process. FcRn affinity refers to the strength of the interaction between FcRn and antibodies. A higher affinity indicates a tighter binding between the two, resulting in enhanced antibody stability, prolonged systemic circulation, and improved antibody bioavailability. The determination of FcRn affinity is essential in the characterization of antibody drugs. It helps in understanding the pharmacokinetics and pharmacodynamics of antibody therapeutics and aids in predicting their efficacy and safety profiles, enabling the selection of candidates with improved therapeutic potential.
Fig. 1 FcRn structure and ligand binding. (Fyzik, M. er al, 2019)
Our FcRn Affinity Assay Services
Creative Proteomics' FcRn affinity assay provides valuable information about the binding kinetics and stability of antibodies with FcRn. This assay is performed using various techniques such as surface plasmon resonance (SPR) or bio-layer interferometry (BLI). Measuring and comparing the binding affinity of different antibodies to FcRn can help clients evaluate the potential therapeutic effect of an antibody drug. Creative Proteomics provides a versatile technology platform that enables accurate detection, including but not limited to the following:
- Bio-layer interferometry (BLI)
BLI is a powerful tool for assessing the affinity of antibody drugs for FcRn. In the BLI method, a biosensor with a high-refractive index layer is used to measure the interference pattern created by the binding of an antibody to FcRn. This biosensor is coated with FcRn, allowing for specific antibody-FcRn interactions to occur. When an antibody binds to FcRn, it induces a change in the interference pattern, which is detected by an optical system.
Our advanced BLI technology eliminates the need for fluorescent or radioactive labeling of antibodies and provides real-time measurements that allow for the study of kinetic parameters such as association and dissociation rates. This dynamic information is essential for understanding the binding mechanism of antibodies to FcRn.
- Surface plasmon resonance (SPR)
To perform FcRn affinity measurements, different concentrations of the antibody drug are injected over the immobilized FcRn receptor, and the resulting binding response is recorded. By analyzing the binding response as a function of drug concentration, a binding curve can be generated. The affinity, or binding strength, of the antibody drug for FcRn can then be determined by fitting the binding curve to an appropriate binding model. By this method we can provide valuable information about the FcRn affinity of an antibody drug, such as the dissociation constant (Kd) as well as the kinetics of drug-receptor binding, including the binding rate constant (kon) and dissociation rate constant (koff).
Service Highlights
- Professional technical team and more than ten years of rich technical experience.
- Allowing for the analysis of multiple samples simultaneously.
- Different antibody concentrations, assay formats and experimental conditions were adjusted to specific requirements and goals to optimize assay performance and sensitivity.
Creative Proteomics combines our expertise with state-of-the-art testing platforms to help clients around the world realize the acceleration of their antibody drug development process. Contact us to learn more about our FcRn affinity assay service of antibody drugs. We will be happy to serve you.
Reference
- Pyzik, M.; et al. The Neonatal Fc Receptor (FcRn): A Misnomer? Front Immunol. 2019 Jul 10; 10: 1540.
